Study: Prostate cancer risk assessment plus PSA could reduce unnecessary biopsies
This article was originally published in Clinica
Executive Summary
Prostate-specific antigen (PSA) screening for prostate cancer combined with a new method of risk assessment could cut the number of unnecessary biopsies, a study has found.